Skip to content

Analgesic Efficacy of Oxycodone Combined with Bilateral Modified Thoracoabdominal Nerves Block through Perichondrial Approach (M-TAPA) for Laparoscopic Radical Gastrectomy

Analgesic Efficacy of Oxycodone Combined with Bilateral Modified Thoracoabdominal Nerves Block through Perichondrial Approach (M-TAPA) for Laparoscopic Radical Gastrectomy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119394
Enrollment
Unknown
Registered
2026-02-26
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Analgesia for Laparoscopic Radical Gastrectomy

Interventions

Group Oxycodone:PCIA:oxycodone 0.8 mg/kg combined with ondansetron 8 mg (mixed in the PCIA pump solution to a volume of 100 mL) (no background infusion, bolus of 2 mL, lockout time of 10 min).
Group Sufentanil:PCIA:sufentanil 2 ug/kg combined with ondansetron 8 mg (mixed in the PCIA pump solution to a volume of 100 mL) (no background infusion, bolus of 2 mL, lockout time of 10 min).

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18 to 75 years old, of either gender. 2. Body Mass Index (BMI): 18 to 30 kg/m². 3. Surgery: Patients scheduled for elective laparoscopic radical gastrectomy. 4. ASA Physical Status: American Society of Anesthesiologists (ASA) physical status I to III. 5. Informed Consent: Patients who provided written informed consent and voluntarily agreed to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Patients who explicitly refused to participate in the study. 2. Body Mass Index (BMI) > 30 kg/m²; or a history of severe cardiovascular, cerebrovascular, pulmonary, hepatic, renal, or metabolic diseases. 3. Long-term use of opioids or analgesics before surgery; or a history of abnormal recovery from previous anesthesia or surgery. 4. Severe hepatic or renal insufficiency (Child-Pugh class C or estimated glomerular filtration rate [eGFR] 1.5 or platelet count < 80 × 10?/L). 7. Presence of skin infection or inflammation at the intended puncture site. 8. Any other condition that, in the investigator's opinion, made the patient unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
The 15-item recovery quality scale at 24 hours after surgery (global score Quality of Recovery-15 scale, QoR-15);

Secondary

MeasureTime frame
Pain score;PCIA total compressions ;PCIA effective compressions ;Total opioid consumption from 0 to 24 hours postoperatively will be calculated as intravenous morphine equivalents (IME, mg);Incidence of postoperative nausea and vomiting (PONV);Incidence of sedation;Incidence of respiratory depression ;Time to first flatus;The QoR-15 at 48h after surgery ;Time to first oral intake;The time of removing the gastric tube;The time of removing the urinary catheter;time of first postoperative mobilization ;

Countries

China

Contacts

Public ContactDanxu Ma

Beijing Friendship Hospital, Capital Medical University,

madanxu@126.com+86 158 0130 9138

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026